SOUTH SAN FRANCISCO, Calif., June 18 /PRNewswire-FirstCall/ -- RigelPharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, thecompany's chairman and chief executive officer, will be presenting a companyoverview at the Jefferies 2nd Annual Healthcare Conference in New York onThursday, June 26 at 11:45 a.m. EDT.
To access the live audio webcast or the subsequent archived recording, logon to http://www.rigel.com. Please connect to Rigel's website several minutesprior to the start of the live webcast to ensure adequate time for anysoftware download that may be necessary.
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers anddevelops novel, small-molecule drugs for the treatment ofinflammatory/autoimmune diseases and cancer, as well as viral and metabolicdiseases. Our pioneering research focuses on intracellular signaling pathwaysand related targets that are critical to disease mechanisms. Rigel'sproductivity has resulted in strategic collaborations with largepharmaceutical partners to develop and market our product candidates. Rigelhas product development programs in inflammatory/autoimmune diseases such asrheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
SOURCE Rigel Pharmaceuticals, Inc.
